Bicocca Open Archive

Logo unimib boa
CAZZANIGA, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 36.168
AS - Asia 17.338
EU - Europa 14.165
SA - Sud America 2.636
Continente sconosciuto - Info sul continente non disponibili 1.296
AF - Africa 401
OC - Oceania 37
Totale 72.041
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 34.170
SG - Singapore 6.050
IT - Italia 4.257
CN - Cina 3.465
HK - Hong Kong 2.509
VN - Vietnam 2.455
RU - Federazione Russa 2.048
BR - Brasile 1.921
CA - Canada 1.631
DE - Germania 1.414
IE - Irlanda 1.396
SE - Svezia 1.380
UA - Ucraina 783
GB - Regno Unito 690
BD - Bangladesh 602
FR - Francia 602
IN - India 474
FI - Finlandia 368
AR - Argentina 251
AT - Austria 248
ID - Indonesia 245
KR - Corea 221
TR - Turchia 220
NL - Olanda 198
ES - Italia 191
IQ - Iraq 185
MX - Messico 152
PK - Pakistan 143
JP - Giappone 137
ZA - Sudafrica 122
PL - Polonia 113
SA - Arabia Saudita 111
EC - Ecuador 105
CO - Colombia 101
VE - Venezuela 84
PH - Filippine 83
DK - Danimarca 80
BE - Belgio 71
CH - Svizzera 68
UZ - Uzbekistan 59
JM - Giamaica 58
CL - Cile 47
PY - Paraguay 45
EG - Egitto 43
MA - Marocco 42
MY - Malesia 41
CZ - Repubblica Ceca 40
KE - Kenya 39
JO - Giordania 37
PE - Perù 35
AE - Emirati Arabi Uniti 34
CR - Costa Rica 33
TN - Tunisia 31
ET - Etiopia 30
AU - Australia 28
GR - Grecia 28
IL - Israele 27
KZ - Kazakistan 25
PT - Portogallo 25
TH - Thailandia 25
NP - Nepal 24
LT - Lituania 23
AZ - Azerbaigian 22
BG - Bulgaria 22
LB - Libano 22
TT - Trinidad e Tobago 22
UY - Uruguay 22
DZ - Algeria 20
RO - Romania 19
TW - Taiwan 18
BO - Bolivia 16
EU - Europa 16
IR - Iran 16
NI - Nicaragua 16
OM - Oman 16
AL - Albania 15
EE - Estonia 14
GT - Guatemala 13
HN - Honduras 13
NO - Norvegia 12
PA - Panama 12
SN - Senegal 12
DO - Repubblica Dominicana 11
AO - Angola 10
SV - El Salvador 10
BY - Bielorussia 9
HR - Croazia 9
KG - Kirghizistan 9
NG - Nigeria 9
BH - Bahrain 8
HU - Ungheria 8
MU - Mauritius 8
RS - Serbia 8
BB - Barbados 7
KW - Kuwait 7
LK - Sri Lanka 7
SY - Repubblica araba siriana 7
GE - Georgia 6
LV - Lettonia 6
NZ - Nuova Zelanda 6
Totale 70.646
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.634
Singapore 3.506
Ashburn 3.417
Hong Kong 2.456
Fairfield 2.293
Woodbridge 2.115
San Jose 1.856
Houston 1.709
Dublin 1.361
Milan 1.284
Chandler 1.252
Toronto 1.217
Wilmington 1.071
Seattle 916
Frankfurt am Main 850
New York 804
Cambridge 799
Jacksonville 771
Ho Chi Minh City 754
Santa Clara 725
Dearborn 605
Council Bluffs 570
Los Angeles 566
Hanoi 548
Chicago 537
Beijing 520
Princeton 500
Dallas 420
The Dalles 400
Hefei 374
Rome 297
Lauterbourg 257
Lawrence 239
Nanjing 233
Altamura 224
Shanghai 217
Moscow 216
Buffalo 214
Seoul 202
Vienna 189
São Paulo 185
Jakarta 167
San Diego 166
Boardman 165
Helsinki 152
Phoenix 130
Lachine 124
Orem 116
Munich 114
Brooklyn 112
Columbus 109
Montreal 102
Guangzhou 98
Denver 96
London 95
Lissone 94
Warsaw 94
Nuremberg 89
Tokyo 87
Dong Ket 80
Nanchang 80
Andover 79
Atlanta 77
Da Nang 76
Haiphong 76
Baghdad 75
Naples 68
Shenyang 67
Salt Lake City 66
Chennai 65
Tianjin 65
Brussels 64
Changsha 64
Turin 64
Fuzhou 63
Rio de Janeiro 63
Paris 56
Hebei 55
Jinan 53
Stockholm 53
Zurich 53
Philadelphia 52
San Francisco 51
Miami 50
Figino 49
Johannesburg 49
Poplar 49
Tashkent 48
Bologna 47
Norwalk 45
Amsterdam 44
Boston 44
Biên Hòa 43
Brasília 43
Hải Dương 43
Turku 43
Lappeenranta 41
Manchester 41
Zhengzhou 41
Belo Horizonte 39
Totale 44.737
Salva come PNG Salva come JPEG
Nome #
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 573
BEYOND THE TUMOUR: CHILDHOOD CANCER PREDISPOSING SYNDROMES [Guardare oltre il tumore: le cancer-predisposingsyndrome in età pediatrica] 556
Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development 535
Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche 511
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 495
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies 481
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 478
IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia 475
Clinical features and outcome of SIL/TAL1-positive t-cell acute lymphoblastic leukemia in children and adolescents: A 10-year experience of the AIEOP group 473
NIPBL: a new player in myeloid cells differentiation 469
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia 451
Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation 446
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 443
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 438
A simple RNA target capture NGS strategy for fusion genes assessment in the diagnostics of pediatric B-cell acute lymphoblastic leukemia 433
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 421
Idiopathic erythrocytosis: a germline disease? 418
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL 404
Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation 401
Phenotypical and Functional Characterization of Mesenchymal Stem Cells Derived From Patients Affected by Schwachman-Diamond Syndrome 401
Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis 395
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 395
Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia 386
Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection 383
The bone marrow niche in b-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia 377
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression 376
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 370
Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL 368
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 359
Cytoskeletal Regulatory Gene Expression and Migratory Properties of B Cell Progenitors are Affected by the ETV6-RUNX1 Rearrangement 354
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting 347
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 347
Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations 347
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 337
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study 337
SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia 337
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection 335
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia 334
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 331
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome 331
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 328
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia 328
Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model 328
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 324
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia 324
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 319
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 319
PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells 316
Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform 311
Characterization of children with FLT3-ITD acute myeloid leukemia: A report from the AIEOP AML-2002 study group 311
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 310
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 310
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 309
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 307
Clinico-biologic features of 5202 acute lymphoblastic leukemia patients enrolled in the Italian AIEOP and GIMEMA Protocols and stratified in age-cohorts 306
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 306
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia 305
Antibody Deficiency in Patients with Biallelic KARS1 Mutations 303
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype 302
Abnormal B-Cell Maturation and Increased Transitional B Cells in CBL Syndrome 300
Fine Tuning of Surface CRLF2 Expression and Its Associated Signalling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia 298
Metabolic gatekeeper function of B-lymphoid transcription factors 297
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells 296
LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients 295
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 295
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 294
Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects 292
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening 290
Exploring glioblastoma heterogeneity: the impact of ecDNA on tumor evolution and progression 289
PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5 289
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 288
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia 288
Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement 288
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? 285
IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia 284
The KMT2A recombinome of acute leukemias in 2023 282
Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: Another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma 282
Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis 282
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome 281
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 281
What is the relevance of Ikaros gene deletions as prognostic marker in pediatric Philadelphia negative B-cell precursor acute lymphoblastic leukemia? 281
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial 280
Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia 279
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols 279
Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation 278
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia 278
Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia 277
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 277
DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4 276
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 276
Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia 275
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study 275
Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response 275
Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL 275
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 272
Potential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies 271
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study 269
High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias 267
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: Revisited in AIEOP-BFM protocol 267
Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". 265
Totale 33.982
Salva come PNG Salva come JPEG
Categoria #
all - tutte 235.749
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 235.749
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.285 0 0 0 237 256 271 123 177 208 230 227 556
2022/20235.119 663 1.625 374 426 282 793 67 292 332 31 154 80
2023/20244.081 119 130 173 185 528 1.087 816 152 357 85 81 368
2024/20259.831 466 1.067 552 447 866 311 662 292 1.069 1.516 861 1.722
2025/202625.540 3.009 1.663 1.751 2.696 2.926 1.262 3.118 1.250 1.825 2.067 2.045 1.928
2026/20276.168 994 1.205 2.829 1.140 0 0 0 0 0 0 0 0
Totale 72.041